Study of Eye Movements as Markers of the Physiological, Cerebral and Cognitive State of Healthy Subjects (EyeProxy)

May 6, 2022 updated by: University Hospital, Grenoble
The goal of this study is the multimodal exploration via eyetracking, MRI and EEG data of ocular movements and the corresponding brain activation during ecologic visual stimulation in the healthy population.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Cerebral activation following visual stimulation is explored using two neuroimaging techniques EEG and MRI while eye movements are recorded. Three experiments are performed: in MR scanner 1) functional localisation of specific areas: LOC, FFA, MT/V5, V1 and V2 and 2) a saccadic choice experiment; with EEG, replication of the experiments performed in the MR scanner and 3) an additional experiment of movement detection during the ocular saccades.

Thirty young volunteers (18-40 y old) are involved.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Grenoble, France, 38043
        • CHU Grenoble Alpes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Normal vision or corrected to normal
  • Social security affiliation
  • Signed consent to participate
  • No pregnancy fo women

Exclusion Criteria:

  • Audition and motor troubles
  • Incapable to decide (Persons mentioned in L1121-5,6 et 8 of public health code)
  • Neurological disorders
  • Pathology affecting oculomotor control
  • MRI incompatibility

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Healthy Subjects
All healthy subject are gathered in one arm
Other: Neuroimaging
MR, EEG recordings

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Eye movement brain networks
Time Frame: 24 months
Identification of the cerebral locus of ocular movement via MRI & EEG
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OculoDB
Time Frame: 24 months
Database repository of healthy population
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Grenoble

Collaborators

Grenoble Institut des Neurosciences
GIPSA-LAB

Investigators

  • Principal Investigator: Sara MEONI, PH, University Hospital, Grenoble

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 16, 2020

Primary Completion (Actual)

July 22, 2021

Study Completion (Actual)

July 22, 2021

Study Registration Dates

First Submitted

March 25, 2020

First Submitted That Met QC Criteria

March 27, 2020

First Posted (Actual)

March 30, 2020

Study Record Updates

Last Update Posted (Actual)

May 9, 2022

Last Update Submitted That Met QC Criteria

May 6, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 38RC20.063

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe